Clik here to view.
Now What? Post-Election and FDA
We are finally post-election. The sense of relief that one can watch or listen to broadcast television or radio without seeing campaign ads is still being felt nationwide. Facebook sidebars are free...
View ArticleClik here to view.
Election Impact – The New Class
Around elections, I have usually tried to provide some insight into where candidates stood on health care related issues, particularly affecting the development and marketing of medical products. I...
View ArticleClik here to view.
Is There a Doctor in the House? The Medical Background of Congress
Congress oversees a great deal that has to do with health care. You may have heard a little about that little piece of legislation that was passed called the Affordable Care Act (a/k/a Obamacare),...
View ArticleClik here to view.
Legislative Proposals in the 114th Congress
Every so often, EyeonFDA has an update for you on legislation that is proposed in the Congress that would impact the medical product marketplace if passed. The new Congress has just two months old...
View ArticleClik here to view.
This is Your State – This is Your State on Drugs
In years gone by, I have taken occasion to write a posting with this title to take a look at the policy activity that is going on at the state level that impacts medicines. It has been a few years...
View ArticleClik here to view.
This is Your State, This is Your State on Drugs
I always enjoy doing a periodic check in on what states are doing when it comes to healthcare issues. Utilizing the excellent data base resources at the National Conference of State Legislatures, one...
View ArticleClik here to view.
Local Ballot Initiatives Impacting Health and Healthcare
There is a good deal of commentary about what happened at the nationally in this year’s election cycle. But a good deal happened at the state level as well – things that will impact healthcare and may...
View ArticleClik here to view.
New Directions for FDA, Part 1 – 21st Century Cures
One of the often stated priorities for lame-duck Congress has been voting on the 21st Century Cures Act. In a press release from Saturday, November 26 from the House Energy and Commerce Committee, the...
View ArticleClik here to view.
New Directions for FDA, Part 2 – Regulatory Matters
In Part 1 about change facing FDA, we looked at the 21st Century Cures Act and some of the change that would be in store for FDA. But in this post-election cycle, there is more than pending...
View ArticleClik here to view.
Healthcare Reform – Where Are We? – An Invitation
Over the past three decades, we have gone from Hillarycare to Obamacare to Trumpcare. The mere fact that healthcare is characterized by the names of public figures is testament to the extreme...
View Article
